Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort

Michel Aubier1 Inserm UMR1152, Physiopathology and Epidemiology of Respiratory Diseases, Paris, France, [email protected];2 Faculty of Medicine, Paris Diderot University, Paris, France, [email protected];3 Laboratory of Excellence, INFLAMEX, Université Sorbonne Paris Cité and DHU FIRE, Paris, France, [email protected];4 Pneumology A Department, Bichat-Claude-Bernard University Hospital, Paris, France, [email protected]Correspondence[email protected]

Gabriel Thabut1 Inserm UMR1152, Physiopathology and Epidemiology of Respiratory Diseases, Paris, France, [email protected];2 Faculty of Medicine, Paris Diderot University, Paris, France, [email protected];3 Laboratory of Excellence, INFLAMEX, Université Sorbonne Paris Cité and DHU FIRE, Paris, France, [email protected];5 Pneumology B Department, Bichat-Claude-Bernard University Hospital, Paris, France

Caroline Fabry-Vendrand6 Epidemiology and Research Partnerships, AstraZeneca, Courbevoie, France

Pages 217-224 | Published online: 31 Aug 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

DelmasMCFuhrmanCfor the Epidemiology and Research Group SPLF ClinicAsthma in France: a review of descriptive epidemiological dataRev Mal Respir2010272151159 French20206063
PubMed Web of Science ®Google Scholar
ToTStanojevicSMooresGGlobal asthma prevalence in adults: findings from the cross-sectional world health surveyBMC Public Health20121220422429515
PubMed Web of Science ®Google Scholar
ChungKFWenzelSEBrozekJLInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEur Respir J201443234337324337046
PubMed Web of Science ®Google Scholar
PetersSPFergusonGDenizYReisnerCUncontrolled asthma: a review of the prevalence, disease burden and options for treatmentRespir Med200610071139115116713224
PubMed Web of Science ®Google Scholar
GadenneSPribilCChouaidCVergnenegreADetournayBLe coût de l’asthme en France et les implications économiques du niveau de contrôle [The costs of asthma in France and the economic implications of its level of control]Rev Mal Respir2011284419426 French21549898
PubMed Web of Science ®Google Scholar
DurhamALCaramoriGChungKFAdcockIMTargeted anti-inflammatory therapeutics in asthma and chronic obstructive lung diseaseTransl Res2016167119220326334389
PubMed Web of Science ®Google Scholar
PriceDWilsonAMChisholmAPredicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practiceJ Asthma Allergy2016911226793004
PubMedGoogle Scholar
TaliniDNovelliFBacciESputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational studyBMJ Open201551e005748
PubMed Web of Science ®Google Scholar
BeldaJParameswaranKLemièreCKamadaDO’ByrnePMHargreaveFEPredictors of loss of asthma control induced by corticosteroid withdrawalCan Respir J200613312913316642226
PubMedGoogle Scholar
KolbeckRKozhichAKoikeMMEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJ Allergy Clin Immunol201012561344135320513525
PubMed Web of Science ®Google Scholar
FitzGeraldJMBleeckerERNairPBenralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialLancet2016388100562128214127609406
PubMed Web of Science ®Google Scholar
BleeckerERFitzGeraldJMChanezPEfficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialLancet2016388100562115212727609408
PubMed Web of Science ®Google Scholar
Fasenra™. (benralizumab) Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004433/WC500245331.pdfAccessed April 5, 2018
Google Scholar
Epidemiologie—France PortalCOBRA—Asthma and Airway Obstruction Cohort: Clinicobiological Cohort Follow-up2014 Available from: https://epidemiologie-France.aviesan.fr/en/epidemiology/records/asthma-and-airway-obstruction-cohort-clinicobiological-cohort-follow-upAccessed October 12, 2017
Google Scholar
PretolaniMSoussanDPoirierIThabutGAubierMon behalf of the COBRA Study GroupClinical and biological characteristics of the French COBRA cohort of adult subjects with asthmaEur Respir J2017502170001928838976
PubMed Web of Science ®Google Scholar
FitzGeraldJMBleeckerERMenzies-GowAPredictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studiesLancet Respir Med201861516428919200
PubMed Web of Science ®Google Scholar
GoldmanMHirschIZangrilliJGNewboldPXuXThe association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studiesCurr Med Res Opin20173391605161328644104
PubMed Web of Science ®Google Scholar
AustinDPouliquenIKeeneOYanceySBlood eosinophil dose response to oral corticosteroids in a population of patients with severe asthmaEur Respir J201648PA1110
Web of Science ®Google Scholar
NairPWenzelSRabeKFOral glucocorticoid–sparing effect of benralizumab in severe asthmaN Engl J Med2017376252448245828530840
PubMed Web of Science ®Google Scholar
BatemanEDHurdSSBarnesPJGlobal strategy for asthma management and prevention: GINA executive summaryEur Respir J200831114317818166595
PubMed Web of Science ®Google Scholar
Global Initiative for AsthmaGlobal strategy for asthma management and prevention2017 Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/Accessed October 12, 2017
Google Scholar
Xolair^®. (omalizumab) Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdfAccessed October 12, 2017
Google Scholar
Nucala^®. (mepolizumab) Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003860/WC500198037.pdfAccessed October 12, 2017
Google Scholar
CINQAERO^®. (reslizumab) Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003912/WC500212250.pdfAccessed October 12, 2017
Google Scholar
AlbersFCMüllerováHGunsoyNBBiologic treatment eligibility for real-world patients with severe asthma: The IDEAL studyJ Asthma20185521928463581
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date